Travere Therapeutics (TVTX) Stock Price
Travere Therapeutics Price
Travere Therapeutics (TVTX) Stock | ISIN US89422G1076 | WKN A2QHYP. The current Travere Therapeutics stock price is 48.88 USD (2026). Revenue is 710.34 M USD. Net income is 53.29 M USD. The P/E ratio is 72.36. Market capitalization is 3.86 B USD. Travere Therapeutics operates in the Health sector.
Travere Therapeutics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Travere Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Travere Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Travere Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Travere Therapeutics Price |
|---|
Travere Therapeutics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Travere Therapeutics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Travere Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Travere Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Travere Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Travere Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Travere Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Travere Therapeutics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Travere Therapeutics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Travere Therapeutics business model & stock analysis
Travere Therapeutics SWOT Analysis
Strengths
Travere Therapeutics Inc has several strengths that contribute to its success. These include:
- Strong research and development capabilities
- Innovative pipeline of potential therapeutics
- Experienced and knowledgeable management team
- Solid financial position
Weaknesses
Despite its strengths, Travere Therapeutics Inc also has weaknesses that need to be addressed:
- Limited product portfolio
- Reliance on external partnerships for certain drug development projects
- Vulnerability to regulatory changes and uncertainties
- Highly competitive industry
Opportunities
Travere Therapeutics Inc has opportunities to further expand and improve its position in the market:
- Potential for strategic collaborations and partnerships
- Growing global demand for innovative therapies
- Advancements in technology that can enhance drug discovery and development processes
Threats
However, there are also several threats that Travere Therapeutics Inc should be aware of and address:
- Intense competition from established and emerging biopharmaceutical companies
- Stringent regulatory approvals and compliance requirements
- Potential failure of clinical trials and setbacks in drug development
- Economic and political factors impacting the healthcare industry
Travere Therapeutics Segments
Travere Therapeutics Revenue by Segment (1/5)
Max
Details
Travere Therapeutics Revenue by Segment (2/5)
3 Years
5 Years
10 Years
25 Years
Max
Details
Travere Therapeutics Revenue by Segment (3/5)
3 Years
5 Years
10 Years
25 Years
Max
Details
Travere Therapeutics Revenue by Segment (4/5)
Max
Details
Travere Therapeutics Revenue by Segment (5/5)
Max
Details
Travere Therapeutics Eulerpool Fair Value
Travere Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio
Travere Therapeutics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Travere Therapeutics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Travere Therapeutics Earnings Estimates
Travere Therapeutics Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 4/30/2026 | -0.22USD | 139.43 MUSD | 2026 Q1 |
| 2/19/2026 | -0.04USD | 147.72 MUSD | 2025 Q4 |
| 2/18/2026 | -0.04USD | 147.72 MUSD | 2025 Q4 |
| 5/2/2024 | -1.1USD | 47.13 MUSD | 2024 Q1 |
| 2/21/2024 | -1.25USD | 41.85 MUSD | 2023 Q4 |
| 8/2/2023 | -0.85USD | 56.19 MUSD | 2023 Q2 |
| 5/3/2023 | -0.71USD | 69.86 MUSD | 2023 Q1 |
| 2/22/2023 | -0.99USD | 59.32 MUSD | 2022 Q4 |
| 10/27/2022 | -0.88USD | 55.58 MUSD | 2022 Q3 |
| 8/4/2022 | -0.89USD | 50.37 MUSD | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Travere Therapeutics stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Travere Therapeutics shareholder structure
| % | Name |
|---|---|
14.37447% | |
11.25127% | |
8.48195% | |
7.5746% | |
6.4616% | |
5.69867% | |
4.41529% | |
4.24357% | |
3.52901% | |
3.16282% |
Travere Therapeutics Executives and Management Board
Dr. Eric Dube
(52)President, Chief Executive Officer, Director · since 2019
Ms. Elizabeth Reed
(54)Chief Legal Officer, General Counsel and Corporate Secretary
Dr. Jula Inrig
(50)Chief Medical Officer
Dr. William Rote
(62)Chief Research Officer
Mr. Peter Heerma
(54)Chief Commercial Officer
Travere Therapeutics Supply Chain
Frequently asked questions about Travere Therapeutics
The business model of Travere Therapeutics Inc revolves around developing and commercializing transformative therapies to address rare and serious diseases. By focusing on areas of high unmet medical need, Travere Therapeutics aims to make a meaningful impact on the lives of patients and their families. Leveraging its expertise in research and development, the company strives to identify potential treatment options and deliver innovative solutions to improve patient outcomes. Travere Therapeutics Inc aims to collaborate with healthcare professionals, regulators, and patient advocacy groups to ensure that its therapies reach those who need them the most, providing hope and improving quality of life.
Travere Therapeutics stock
Travere Therapeutics Peer Group
Travere Therapeutics Ticker
Travere Therapeutics FIGI
All fundamentals and in-depth analysis of Travere Therapeutics
Our stock analysis for Travere Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Travere Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.